Dementia-Focused VC Fund Hopes To Succeed Where Other Research Strategies Have Not
This article was originally published in The Pink Sheet Daily
A group of pharmaceutical companies, charities and the UK government are funding the first venture capital fund targeted against a specific condition, dementia.
You may also be interested in...
The number of drug candidates in development for Alzheimer's is at its highest-ever level and despite the lack of success to date, biopharma companies continue to believe the potential rewards are worth the risk. As R&D in the field accelerates, therapies that treat not only symptoms of the disease but also slow its progression are expected to arrive sooner rather than later.
The G8 dementia summit saw politicians, health stakeholders and financiers agree to target Alzheimer’s disease together, but a silver bullet may be years away.
An effort to close the venture funding gap with the U.S. gets potential help in several ways.